Erratum: Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC (Annals of Oncology (2017) 28 (1339–1345) DOI: 10.1093/annonc/mdx075)

J. J. Knox, C. H. Barrios, T. M. Kim, T. Cosgriff, V. Srimuninnimit, K. Pittman, R. Sabbatini, S. Y. Rha, T. W. Flaig, R. D. Page, J. T. Beck, F. Cheung, S. Yadav, P. Patel, L. Geoffrois, J. Niolat, N. Berkowitz, M. Marker, D. Chen, R. J. Motzer

Research output: Contribution to journalComment/debate

Abstract

In the original article, Figure 2B incorrectly described the curves as PFS, while it should have read OS. This has now been corrected.

Original languageEnglish
Article number2269
JournalAnnals of Oncology
Volume29
Issue number11
DOIs
Publication statusPublished - 2018

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Erratum: Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC (Annals of Oncology (2017) 28 (1339–1345) DOI: 10.1093/annonc/mdx075)'. Together they form a unique fingerprint.

  • Cite this

    Knox, J. J., Barrios, C. H., Kim, T. M., Cosgriff, T., Srimuninnimit, V., Pittman, K., Sabbatini, R., Rha, S. Y., Flaig, T. W., Page, R. D., Beck, J. T., Cheung, F., Yadav, S., Patel, P., Geoffrois, L., Niolat, J., Berkowitz, N., Marker, M., Chen, D., & Motzer, R. J. (2018). Erratum: Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC (Annals of Oncology (2017) 28 (1339–1345) DOI: 10.1093/annonc/mdx075). Annals of Oncology, 29(11), [2269]. https://doi.org/10.1093/annonc/mdx807